By its location at the plasma membrane only in neoplastic cells in cHL, diffuse large B cell lymphoma (DLBCL), and anaplastic large cell lymphoma (ALCL), CYB5B might be an attractive target for antibody-based therapy as toxicity should be minimal since normal, reactive lymphocytes and CD34+ bone marrow precursor cells do not express the protein at the plasma membrane [258]. Here, CYB5B is linked to anaplastic large cell lymphoma.